Skip to main content
. 2021 Apr 15;131(8):e146394. doi: 10.1172/JCI146394

Figure 1. Four major steps in autologous hematopoietic stem cell (HSC) therapies to treat SCD.

Figure 1

(i) Clinical researchers inform participants about the procedure, associated risks, and alternative treatments, then obtain written consent. (ii) CD34+ HSPCs are mobilized with plerixafor and isolated from blood by apheresis. (iii) HSPCs are manipulated ex vivo to correct the SCD mutation or induce HbF expression. (iv) The participant receives bone marrow conditioning with myelotoxic/myeloablative agents, followed by infusion of the modified HSPCs.